



Mills Oakley advises MediPharm Labs Inc. on aggregated C\$38.7 million credit facility

16 October, 2019

National law firm Mills Oakley has advised on an aggregated C\$38.7 million credit facility between a leading global cannabis extraction company, MediPharm Labs Inc. (a wholly owned subsidiary of listed company MediPharm Labs Corp. (TSX: LABS)), and a top 5 Canadian Schedule 1 bank. The financing comprises various facilities that can be drawn in both Canadian and Australian dollars. This transaction comes off the back of a recent C\$75 million bought deal equity offering.

Mills Oakley was appointed local counsel for MediPharm Labs Corp., its wholly owned subsidiary MediPharm Labs Inc., and its Australian subsidiary MediPharm Labs Australia. The MediPharm group are considered a global leader in specialised, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, and are an important client for the firm.

Banking & Finance partner Monique Stella, Senior Associate Isabella Barnes and Law Graduate Will Constable of our Melbourne office assisted Aird & Berlis LLP who acted for the group as Canadian counsel. Cassels Brock & Blackwell LLP (Canada) and Ashurst LLP (Melbourne) acted for the bank.

Media Contact:

Renu Prasad

Communications Manager

T: +61 2 8289 5820

E: rprasad@millsoakley.com.au